Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman...
Login to comment.